Clinical trials: Heart Failure With Preserved Ejection Fraction (HFpEF)
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH.
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Trial name
- RENEU-PH (NCT07221513)
- Testing
- JK07
- Where
- United States
- Sponsor
- Salubris Biotherapeutics Inc
HFpEF
Predictors of Poor Prognosis in HFpEF
Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.
- Trial name
- NCT06844032
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Heart Failure With Preserved Ejection Fraction
Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial
Heart Failure (HF) in Australia affects 1-2% of the population. Heart failure with preserved ejection fraction (HFpEF) refers to a syndrome of clinical heart failure without impairment of systolic cardiac function.
- Trial name
- NCT05129722
- Testing
- Low dose combination polydiuretic therapy, Comparator monotherapy empagliflozin
- Where
- 2 sites in Australia
- Volunteers
- 3 people
- Sponsor
- The George Institute
Heart Failure
REALIsM-HF Pilot Study
The study aims to explore two marketed devices providing a multimarker monitoring including physical activity under real-life conditions in patients with heart failure with preserved ejection fraction (HFpEF) and with heart…
- Trial name
- REALIsM-HF (NCT03507439)
- Testing
- AVIVO Mobile Patient Management (MPM) System, VitalPatch biosensor, DynaPort Move Monitor
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 27 people
- Sponsor
- Bayer
Heart Failure with Preserved Ejection Fraction (HFPEF), Heart Failure with Reduced Ejection Fraction
Feasibility and Effectiveness of Eccentric Exercise in Sarcopenic Older Adults with Heart Failure: a Pilot Study
This study is designed to evaluate the safety, feasibility, and effectiveness of a 12-week eccentric exercise program for older adults with sarcopenia (muscle loss) or sarcopenic obesity and chronic heart failure (HF).
- Conditions
- Heart Failure with Preserved Ejection Fraction (HFPEF), Heart Failure with Reduced Ejection Fraction, Sarcopenia in Elderly, Sarcopenic Obesity
- Trial name
- ECLYPSE-HF (NCT06826963)
- Testing
- Aerobic eccentric intervention
- Where
- 2 sites in Italy
- Volunteers
- 15 people
- Sponsor
- Universita di Verona
Heart Failure With Preserved Ejection Fraction (HFPEF)
HFpEF Phenotyping With Echo, Clinical, and Biomarkers
The EPIC-HFpEF registry is a nationwide Italian study that follows people with a specific type of heart failure called HFpEF. About 500 patients will be enrolled from several specialized hospitals and monitored for up to two…
- Trial name
- The EPIC-HFpEF (NCT07642921)
- Volunteers
- 500 people
- Sponsor
- University Of Perugia
Heart, Heart Failure With Preserved Ejection Fraction (HFPEF)
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
- Trial name
- NCT07219511
- Testing
- VS-041
- Where
- 21 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vasa Therapeutics
Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III
PrEcision Pacing in HFpEF: the PEP-HFpEF Trial
The PEP-HFpEF study is a prospective, single-center mechanistic study evaluating personalized heart rate pacing (myPACE) in patients with heart failure with preserved ejection fraction (HFpEF) and existing cardiac physiologic…
- Conditions
- Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association (NYHA) Class II
- Trial name
- NCT07864558
- Testing
- Individualized myPACE pacemaker programming
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Tufts Medical Center
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Chronic Heart Failure
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.
- Trial name
- RENEU-HF (NCT06369298)
- Testing
- JK07
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 282 people
- Sponsor
- Salubris Biotherapeutics Inc
Pulmonary Hypertension Due to Left Heart Disease, Heart Failure With Preserved Ejection Fraction
Training in HFpEF-PH
Exercise interventions alone or as a component of a comprehensive cardiac rehabilitation program for patients with heart failure (HFrEF and HFpEF) have already shown to reduce the risk of hospitalisations due to HF and improved…
- Trial name
- TRAIN HFpEF (NCT05464238)
- Testing
- Exercise rehabilitation, Standard treatment
- Where
- 2 sites in Germany, Lithuania
- Volunteers
- 90 people
- Sponsor
- Heidelberg University
HFpEF - Heart Failure With Preserved Ejection Fraction
The Gut Microbiota and Metabolites in HFpEF
Heart failure (HF) with preserved ejection fraction (HFpEF) has emerged as a critical public health concern. The annual mortality rate for HFpEF is approximately 15%, accompanied by a re-hospitalization rate of nearly 80%.
- Trial name
- NCT06645535
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF)
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
This is a multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in Chinese subjects with heart failure with ejection fraction retention/mild ejection fraction…
- Conditions
- Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction
- Trial name
- NCT06862908
- Testing
- IBI362
- Where
- China
- Volunteers
- 141 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
This is a study in adults with chronic heart failure. People with chronic heart failure may need to be hospitalised for their condition. Some people with chronic heart failure may eventually die from their condition.
- Trial name
- NCT03057951
- Testing
- Empagliflozin
- Where
- 619 sites in United States, Argentina and 21 more
- Volunteers
- 5,988 people
- Sponsor
- Boehringer Ingelheim
Aortic Valve Stenosis, Heart Failure
ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement
The goal of this trial is to to determine whether use of a novel SGLT2 inhibitor, Enavogliflozin 0.3 mg once daily is superior to placebo, when added to standard-of-care, in reducing the composite of major cardiovascular events…
- Trial name
- ENAVO-TAVR (NCT05672836)
- Testing
- Enavogliflozin, Standard-of-Care
- Where
- 31 sites in South Korea
- Volunteers
- 1,040 people
- Sponsor
- Duk-Woo Park, MD
Heart Failure With Preserved Ejection Fraction
Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
Heart failure with preserved ejection fraction (HFpEF) is a prevalent form of heart failure characterized by impaired left ventricle pressures and diastolic dysfunction.
- Trial name
- NCT06228807
- Testing
- The study involved a comparison of clinical characteristics, medical history, laboratory biomarkers, echocardiographic measurements, angiographic findings, and clinical outcomes between two groups.
- Volunteers
- 584 people
- Sponsor
- Ya-Wei Xu
Heart Failure With Preserved Ejection Fraction, Pulmonary Disease
Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)
Heart failure with preserved ejection fraction (HFpEF) accounts for over 50% of heart failure cases in the United States, affecting a primarily elderly population.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
- Trial name
- NCT01354613
- Testing
- Dobutamine, Amlodipine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
Heart Failure With Preserved Ejection Fraction
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
This is a Phase 2A, randomized, parallel-group, placebo-controlled, double-blind, within subject dose escalation trial with 3 dose levels of HU6 and placebo. Subjects will be randomized (1:1) either to HU6 or placebo.
- Trial name
- HFpEF (NCT05284617)
- Testing
- HU6
- Where
- 15 sites in United States
- Volunteers
- 67 people
- Sponsor
- Rivus Pharmaceuticals, Inc.
Heart Failure With Normal Ejection Fraction
Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of HFpEF
Heart failure (HF) with preserved ejection fraction (HFpEF) has become the most prevalent form of HF in developed countries. Despite its increasing in prevalence, there is no evidence-based effective therapy for HFpEF The purpose…
- Trial name
- TRAINING-HF (NCT02638961)
- Testing
- IMT, FES, Standard treatment
- Where
- Spain
- Volunteers
- 52 people
- Sponsor
- Universitat Jaume I
Type 2 Diabetes, Heart Failure
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07390110
- Testing
- Oral semaglutide, Sitagliptin
- Where
- United States
- Volunteers
- 25,664 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure With Preserved Ejection Fraction
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition…
- Trial name
- DELIVER (NCT03619213)
- Testing
- Dapagliflozin
- Where
- 348 sites in United States, Argentina and 18 more
- Volunteers
- 6,263 people
- Sponsor
- AstraZeneca